Search results
21 mar 2023 · Adoptive immunotherapy targeting Epstein–Barr virus has emerged as a potential therapeutic strategy for the treatment of multiple sclerosis. We have developed a novel manufacturing process, which can offer these T‐cell therapies as an off‐the‐shelf treatment. Introduction.
The central role of Epstein-Barr virus in causing multiple sclerosis is examined to understand how it triggers the disease and presents new opportunities for treatment.
9 lut 2023 · In the first approach, monoclonal antibodies (mAbs) to CD20 are used to kill B cells that harbour latent EBV infection; such mAbs have been approved to treat patients with MS. Targeting of...
5 sie 2022 · We consider how knowledge of EBV-associated cancers may be instructive for understanding the role of EBV in MS and discuss the potential for therapies that target EBV to treat MS....
7 lut 2023 · Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis
5 sie 2022 · Epstein–Barr virus infects most of the human population and, depending on other risk factors, contributes to the development of multiple sclerosis. In this Review, Soldan and Lieberman discuss supporting evidence and potential mechanisms that link Epstein–Barr virus to multiple sclerosis.
17 gru 2020 · Therapy of MS was previously mainly empirical and relied on several low molecular weight (LMW) drugs, including glatiramer acetate, teriflunomide, dimethyl fumarate, fingolimod, cladribine and others, however, biological drugs have been introduced for treatment of RRMS, including beta-interferon and several therapeutic monoclonal Abs (MAbs) (23 ...
